Physical Medicine & Rehabilitation Doctors in Petoskey, MI Accepting Medicare

8 Physical Medicine & Rehabilitation doctors found. Showing 1 - 8

Keith Rose, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3916 Charlevoix Ave, Suite B, Petoskey, MI 49770 Phone: 231-348-1995    Fax: 231-347-3223

Rachel Cook, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 416 Connable Ave, Petoskey, MI 49770 Phone: 800-248-6777

Andrea H Naylor, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 416 Connable Ave, Acute Rehabilitation Unit, Petoskey, MI 49770 Phone: 231-487-3496    Fax: 231-487-3424

Joseph P Sullivan, M.D., PH.D. Physical Medicine & Rehabilitation - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2375 Summit Park Dr, Petoskey, MI 49770 Phone: 231-348-3283    Fax: 231-348-3331

Dr. Gerald Klooster Ii, D.O. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2780 Charlevoix Ave, Suite 19, Petoskey, MI 49770 Phone: 231-347-9800    Fax: 231-347-9850

Adam Ancel, MS ATC PA-S Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2375 Summit Park Dr, Petoskey, MI 49770 Phone: 231-348-3283    Fax: 231-348-3331

Jason Peterman, PAC Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2375 Summit Park Dr, Petoskey, MI 49770 Phone: 231-348-3283    Fax: 231-348-3331

Eugene P. Wang, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2375 Summit Park Dr, Petoskey, MI 49770 Phone: 231-348-3283    Fax: 231-348-3331

News Archive

Targeted therapy combo overcomes treatment resistance in liver cancer

Researchers at the University of Pennsylvania School of Medicine and Abramson Cancer Center reported at the annual meeting of the American Association for Cancer Research that combining two targeted therapies overcomes treatment resistance in liver cancer cell lines.

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.

Maryland's online insurance marketplace plagued by technical issues, discord

The director of the state exchange resigned Friday. Meanwhile, the web portal continues to be marked by operational difficulties that are undermining enrollment efforts.

Challenges for translating pharmacomicrobiomics to personalized medicine

A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.

Read more Medical News

› Verified 7 days ago